[STUDY_ID_REMOVED]  
 
Study ID: RAP‐MD‐01 
 
 
 
Title: A Randomized, Double‐blind, Placebo‐controlled, Multicenter St udy of Rapastinel 
as Adjunctive Therapy in Major Depressive Disorder 
 
 
 
Protocol Amendment 3 Date: 07 Dec 2018 
 
  
Naurex, Inc 1
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].0 TITLE PAGE
A Randomized, Double -blind, Placebo -controlled, Multicenter Study of Rapastinel as 
Adjunctive Therapy in Major Depressive Disorder
RAP -MD-01
IND # 107,974
Sponsor: Naurex Inc., an indir ect subsidiary 
of Allergan, plc
5 Giralda Farms
Madison, NJ [ZIP_CODE]
Original Protocol Date: 28Apr2016
Amendment 1: 28 Sep 2016
Amendment 2: [ADDRESS_177551] 2018
Amendment 3: 07Dec 2018
Confidentiality Statement
This document is the property of Allergan, plc and may not
—in full or part— be passed on, 
reproduced, published, distributed, or submitted to any regulatory authority without the express 
written permission of Allergan, plc.
Naurex, Inc 2
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].0 SYNOPSIS AND SCHEDUL E OF EVALUATIONS
CLINICAL STUDY SYNOPSIS: Stud yRAP -MD-01
Study Number RAP -MD-01
Title of StudyA Randomized, Double -blind, Placebo -controlled, Multicenter 
Study of Rapastinel as Adjunctive Therapy in Major Depressive 
Disorder 
Study Centers (Country) Approximately 35 study centers ([LOCATION_002])
Development Phase 3
ObjectiveTo evaluate the efficacy, safety, and tolerability of rapastinel 
adjunctive to antidepressant therapy (ADT) in patients with major 
depressive disorder (MDD) who have a partial response to ADT
MethodologyMulticenter, randomized, double- blind, placebo -controlled, parallel -
group, 3-week study in patients with MDD who have a partial 
response to ongoing ADT
Number of Patients Approximately 460 planned to be enrolled
Diagnosis and Main Criteria for 
InclusionMale and female outpatients who are 18 to 65 years of age
Meet Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM -5) criteria for MDD ,with a current major 
depressive epi[INVESTIGATOR_153864] 8 weeks and not exceeding 
18months in duration at Visi t 1
 
 
 
Have no more than partial response (< 50% improvement) to 
ongoing treatment with a protocol -allowed ADT   
 
 
 
 
 
 
 
 
 
Test Product, Dosage, and Mode 
of AdministrationRapastinel (450 mg weekly intravenous [IV] administration ) 
adjunctive to ongoing ADT, prefilled sy ringe
Duration of TreatmentUp to14 days of screening and washout period ,followed by a 
3-week double -blind treatment period , followed by a 1-week safety 
follow -
upperiod
Reference Therapy, Dosage, and 
Mode of AdministrationPlacebo adjunctive to ongoing ADT, weekly IV administration , 
prefilled syringe

Naurex, Inc [ADDRESS_177552] 
dose of randomized treatment
 
 
 
 
 
 
 
 
 
 
 
.
Safety MeasuresAdverse event (AE) re cording , clinical laboratory m easures, vital 
sign parameters, electrocardiograms (ECGs), and physical 
examinations
 
 
 
 

Naurex, Inc 4
RAP- MD-01 Protocol Amendment 3 07 Dec 2018Statistical MethodsThe primary efficacy parameter will be the change from baseline in 
MADRS total score at end of study . The primary analysis will be 
performed using a mixed- effects model for repeated measures
(MMRM )with terms for treatment , pooled study center ,visit,and
treatment -by-visit interaction as the fixed effects , and baseline 
MADRS total score, baseline MADRS total score -by-visit as 
covariates . The key secondary efficacy parameter, change from 
baseline in MADRS total score 1day after randomized treatment
will be analyzed using the same MMRM model as was used for the 
primary efficacy parameter. An unstructured covariance matrix will 
be used to model the covariance of within -patient scores. Baseline 
will be defined as the last measurement prior to the first dose of 
double -blind treatment . To control the overall type I error rate for 
both the primary and key secon dary endpoint, a sequential testing 
procedure will be implemented .
All safety parameters will be analyzed using descriptive statistics. 
Safety analyses will be based on the Safety Population, defined as 
all randomized patients who receive at least 1 dose of randomized 
treatment . Efficacy analyses will be based on the modified Intent -
to-Treat ( mITT) Population, defined as all patients who are
randomized and receive at least [ADDRESS_177553] of the Study .......................................................................................................... 12
5.3 Patient Information and Informed Consent ..................................................................................... 12
6.0 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE .................................................... 13
7.0 INTRODUCTION ......................................................................................................................................... 14
8.0 STUDY OBJECTIVES ................................................................................................................................ .18
9.0 INVESTIGATIONAL PLAN ....................................................................................................................... 20
9.1 Overall Study Design and Plan: Description ................................................................................... 20
9.1.1 Screening Period ............................................................................................................... 20
9.1.2 Double -blind Treatment Period ........................................................................................ 20
9.1.3 Safety Follow -up Period ................................................................................................... 21
9.2 Discussion of Study Design, Including the Choice of Control Groups ........................................... 22
9.3 Selection of Study Population ......................................................................................................... 22
9.3.1 Inclusion Criteria .............................................................................................................. 22
9.3.2 Exclusion Criteria ............................................................................................................. 23
9.3.3 Removal of Patients from Therapy or Assessment ........................................................... 27
9.3.4 Patient Replacement Procedures ....................................................................................... 28
9.4 Treatments ....................................................................................................................................... 28
9.4.1 Background Antidepressant Therapy ................................................................................ 28
9.4.2 Treatments Administered .................................................................................................. 29
9.4.3 Identity of Investigational Products .................................................................................. 29
9.4.4 Handling of Investigational Products ................................................................................ 30
9.4.5 Method of Assigning Patients to Treatment Groups ......................................................... 30
9.4.6 Selection of Dosages in the Study .................................................................................... 31
9.4.7 Selection and Timing of Dose for Each Patient ................................................................ 31
Screening Period ............................................................................................. 31 [IP_ADDRESS]
Double -blind Treatment Period ...................................................................... 31 [IP_ADDRESS]
Safety Follow -up Period ................................................................................. 31 [IP_ADDRESS]
9.4.8 Blinding ............................................................................................................................ 31
9.4.9 Unblinding ........................................................................................................................ 32
9.4.10 Prior and Concomitant Therapy ........................................................................................ 32
9.4.11 Other Restrictions ............................................................................................................. 34
Alcohol ........................................................................................................... 34 [IP_ADDRESS]
Contraception .................................................................................................. 34 [IP_ADDRESS]
9.4.12 Monitoring Treatment Compliance ................................................................................... 34
9.4.13 Treatment After Discontinuation ...................................................................................... 34

Naurex, Inc 8
RAP-MD- 01 Protocol Amendment 3 07 Dec [ZIP_CODE].5 Efficacy and Safety Variables ......................................................................................................... 35
9.5.1 Diagnostic and Efficacy Assessments .............................................................................. 35
Diagnostic Assessments .................................................................................. 35 [IP_ADDRESS]
Efficacy Assessments ...................................................................................... 35 [IP_ADDRESS]
9.5.2 Safety Assessments ........................................................................................................... 36
Adverse Events ............................................................................................... 36 [IP_ADDRESS]
Immediate Reporting of Serious Adverse Events and Events of Interest .......40 [IP_ADDRESS]
Reporting of Pregnancies Occurring During the Study .................................. 40 [IP_ADDRESS]
9.6 Data Quality Assurance .................................................................................................................. 55
9.6.1 Data Monitoring ................................................................................................................ 55
9.6.2 Data Recording and Documentation ................................................................................. 55
9.7 Statistical Methods and Determination of Sample Size .................................................................. 56
9.7.1 Analysis Populations ........................................................................................................ 56
Enrolled Population ........................................................................................ 56 [IP_ADDRESS]
Safety Population ............................................................................................ 56 [IP_ADDRESS]
Modified Intent -to-Treat Population ............................................................... 56 [IP_ADDRESS]
9.7.2 Patient Disposition ............................................................................................................ 57
9.7.3 Dem ographics and Other Baseline Characteristics ........................................................... 57
9.7.4 Extent of Exposure and Treatment Compliance ............................................................... 57
Extent of Exposure ................................ ................................
.......................... 57 [IP_ADDRESS]
Measurement of Treatment Compliance ......................................................... 58 [IP_ADDRESS]
9.7.5 Efficacy Analyses ............................................................................................................. 58
Primary Efficacy Parameter ............................................................................ 58 [IP_ADDRESS]
Key Secondary Efficacy Parameter ................................................................ 59 [IP_ADDRESS]
9
9.7.6 Safety Analyses ................................................................................................................ 61
Adverse Events ............................................................................................... 61 [IP_ADDRESS]

Naurex, Inc [ADDRESS_177554] of the Study or Planned Analyses ............................................................ 65
9.10 Protocol Deviations ......................................................................................................................... 66
10.0 STUDY SPO NSORSHIP .............................................................................................................................. 67
10.1 Study Termination ........................................................................................................................... 67
10.2 Reporting and Publication ............................................................................................................... 67
11.0 INVESTIGATOR OBLIGATIONS .............................................................................................................. 68
11.1 Documentation ................................................................................................................................ 68
11.2 Performance .................................................................................................................................... 68
11.3 Use of Investigational Materials ..................................................................................................... 69
11.4 Case Report Forms .......................................................................................................................... 69
11.5 Retention and Revie w of Records ................................................................................................... 69
11.6 Patient Confidentiality .................................................................................................................... 69
12.0 INVESTIGATOR’S STATEMENT ................................
............................................................................. [ADDRESS_177555] OF ABBREVIATIONS
Abbreviation/Term Definition
ADT antidepressant therapy
AE adverse event
ALT alanine aminotransferase 
AST aspartate aminotransferase
ATRQ Antidepressant Treatment Response Questionnaire
BMI body mass index
BP blood pressure
CFR Code of Federal Regulations
CI confidence interval
DSM -[ADDRESS_177556] of 1996
ICF informed consent form
ICH International Conference on Harmonisation 
IND Investigational New Drug (application)
IP investigational product
IRB Institutional Review Board
IV intravenous
IWRS interactive web response s ystem
MADRS Montgomery -Åsberg Depression Rating Scale
MDD major depressive disorder
mITT modified Intent -to-Treat
MMRM mixed -effects model for repeated measures
NMDAR N-methyl -D-aspartate receptor
PCS potentially clinically significant
PID patient identification
QTc QT interval corrected for heart rate
QTcB QT interval corrected for heart rate using the Bazett formula (QTcB =QT/[RR]½)
QTcF QT interval corrected for heart rate using the Fridericia formula (QTcF =QT/[RR]⅓)
SAE serious adverse event
SAP Statistical Analysis Plan
 
SD standard deviation

Naurex, Inc 11
RAP- MD-01 Protocol Amendment 3 07 Dec 2018Abbreviation/Term Definition
SDMT Symbol Digit Modalities Test
SNRI selective serotonin and norepi[INVESTIGATOR_153865] -emergent adverse event
UDS urine drug screen
ULN upper limit of normal
Naurex, Inc [ADDRESS_177557] (I RB) before the start of the study  will be the 
responsibility  of the Investigator. A copy  of the approval letter will be supplied to the Sponsor , 
along with a roster of IRB members or the US Department of Health and Human Services 
general assurance number. During the course of the study , the Investigator will provide timely  
and accurate reports to the I RB on the progress of the study , at intervals not exceeding 1 year (or 
as appropriate), and will notify  the IRB of serious adverse events (SAEs) or other significant 
safet y findings. The study protocol, informed consent form (ICF), information sheet 
advertisements, and amendments (if an y) will be approved b y the IRBs at the study  centers in 
conformance with the US CFR, 
Title 21, Part 56.
5.[ADDRESS_177558] their 
origins in the Declaration of Helsinki.
This clinical study  will comply  with th eICH Guidance on General Considerations for Clinical 
Trials (ICH -E8; 62 FR66113, 17 Dec1997) and GCP (ICH-E6; 62 FR [ZIP_CODE], 09 May 1997), as 
well as Part [ADDRESS_177559] provide written informed consent in compliance with 
21 CFR, Parts 50 and 312 and give HIPAA authorization. 
Each patient will read and sign an ICF and/or other authorization form as per local regulations; 
each patient will be made aware that he or she may withdraw from the stud y at an y time.
The I CF contains all the elements of informed consent listed in Appendix I of this protocol. 
Signed copi[INVESTIGATOR_1093] I CF and the HIPAA or other locally  applicable form will be given to the 
patient, and both documents will be placed in the Investigator’s study  files.
Naurex, Inc [ADDRESS_177560] UDY ADMINISTRATIVE S TRUCTURE
This study  will be performed at approximately  35study  centers in the U nited States.
The Investigator is responsible for ensuring that theinvestigation is conducted according to the 
signed Investigator statement, the investigational plan, GCP guidelines, and applicable 
regulations; for protecting the rights, safet y, and welfare of patients under the Investigator’s care; 
and for the control of investigational products under investigation. An investigator shall obtain 
the informed consent foreach patient prior to the patient enrolling in the study  and/or prior to 
participating in an y study -related activity . 
The Investigator at each s tudy center must meet his or her obligations to the patients, ethics 
committee, Sponsor, and regulatory  authorities b y maintaining oversight and control of the 
study ’s conduct and the study  staff. It is the responsibility  of the Investigator to ensure that an y 
and all delegated duties be assigned to qualified staff by [CONTACT_8640], experience, and licensure (in 
accordance with local regulations) and that the Investigator oversight is documented and 
assessment of staff capabilities and performance is consistent with the study investigational plan. 
The Investigator at eac h study  center will be responsible for the management of the study , 
including maintaining the study  file and the patient records, corresponding with the IRB, and 
completing the electr onic case report forms (eCRFs).
Naurex, Inc 14
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].0 INTRODUCTION
Disease Burden of M ajor Depressive Disorder
Major depressive disorder ( MDD )is a highl y disabling, serious condition which is associated 
with significant morbidity and mortality . MDD manifests as amajor depressive epi[INVESTIGATOR_1865] (which 
may be singular or recurrent) in which the affected individual experiences 1) depressed mood, or
2) loss of interest or pleasure (as well as other s ymptoms ) for most of the day, nearl y every  day,
for at least 2 weeks. MDD affects approximately  14.8 million American adults, or about 6.7 % of 
the US population 18 years of age and older, in a given y ear (Kessler et al, 2005 ). Worldwide, 
about 15% of the adult population is at lifetime risk of developi[INVESTIGATOR_153866] ( Kessler e t al, 1994 ).
Depression may  cause serious, long -lasting s ymptoms and often disrupts a person’s ability  to 
perform routine tasks. In 2000, unipolar depressive disorders were b y far the leading cause 
(11.9%) of worldwide years of life lived with disability  
(World Health Organization, 2001
), and the total economic burden of treating depression in the 
[LOCATION_002] was $83.[ADDRESS_177561] of the total economic burden (62%). Other 
economic burdens in 2000 included $26.1 billion (31%) for treatment costs and $5.4 billion (7%) 
for suicide -related costs ( Greenberg et al, 2003 ). 
MDD is a leadi ng cause of disability  in the [LOCATION_002] ( Murray  et al, 201
3). Moreover, MDD 
is known to be a significant risk factor for suicide and ischemic heart disease, as it accounted for 
16 million of the disability  adjusted life y ears (DALYs) associated with suicide and 4 million of 
the DALYs associated with ischemic heart disease. Research has shown that untreated 
depression has both a functional (social and work role) as well as a neuroanatomical 
(hippocampal shrinkage) effect on the 
patient ( Videbech and Ravnkilde , 2004 ). Given the 
disease burden and link to suicidality  as well as increased mortality  with other comorbid 
conditions, MDD is a serious and life -threatening condition which is a leading cause of disability  
in the world.
Selective Serotonin Reuptake Inhibitors and Selective S erotonin andNorepi[INVESTIGATOR_153867] M ajor Depressive Disorder
Selective serotonin reuptake inhibitors (SSRI s) and selective serotonin and norepi[INVESTIGATOR_153868] (SNRI s)currently  represent the first line of treatment of depressio n in the 
[LOCATION_002]. Unfortunately , a large number of patients do not experience therapeutic benefit 
from these first -line agents ( Rosenzweig -Lipson et al , 2007). Lack of sufficient response to 
adequate treatment remains a critical problem in the management of patients with MDD. Up to 
two-thirds of patients treated with first -line antidepressant monotherap y do not reach full 
remission, and as man y as a third become treatment resistant ( Fava and Davidson, 1996; 
Trivedi et al, 2006). Not achieving remission has been shown to be predictive of p
oorer 
psychosocial functioning, higher rates of relapse ,and higher rates of rehospi[INVESTIGATOR_18543] 
(McInt yreand O’Donovan, 2004 ). 
Naurex, Inc 15
RAP- MD-01 Protocol Amendment 3 07 Dec 2018The results of the STAR*D study  suggest that with successive failures of treatment, patients are 
less and less likely  to respond to subsequent treatment, and those who do respond are more likel y 
to relapse ( Rush et al, 2006 ). Present strategies available to treat patients who do not respond to 
first-line antidepressant monotherap y include switching of antidepressant (either within or 
between cla sses); combination therapy  in which multiple antidepressants are used 
simultaneously ; augmentation of ongoing antidepressant monotherapy  with adjunctive use of 
drugs such as mood stabilizers or aty pi[INVESTIGATOR_16709] ( Boland and Keller, 2006) ;and 
nonpharmacologic treatments including ps ychotherap y and phototherap y, vagus nerve 
stimulation, transcranial magnetic stimulation, and electroconvulsive therapy (ECT) .Clearl y, 
there remains a critically  important unmet medical need for this patient population.
Existing antidepressants have a number of limitations, leading to considerable unmet medical 
need in the effective treatment of MDD ,with up to 50% of patients with MDD having an 
inadequate response or failing current antidepressant therapy  (ADT ). Currently  available first-
line antidepressants (SSRIs, SNRIs) t ypi[INVESTIGATOR_19236] 3 to 4 weeks or more of continuous daily  
dosing to relieve sy mptoms of MDD and are associated with side effects related to their 
pharmacological mechanisms of action (sexual dysfunction, weight gain, jitteriness, sleep 
disturbances) ,which are further associated with poor patient compliance ( Masand 2003, Ashton 
et al, 2005). Patients often experience undesirable side e ffects before they  experience an 
improvement in depressive sy mptoms, which could lead to premature discontinuation of therapy . 
Taken together, these factors define significant areas for improvement of ADT . 
Patients vary  greatl y in their response to antide pressants and it is not possible to reliably  predict 
whether an individual patient will respond to a given antidepressant. This leads to clinicians 
often using a trial -and-error approach to identify  an effective antidepressant. Due to the gradual 
developme nt ofthe full therapeutic effect of currently  available antidepressants, each 
antidepressant needs to be administered for [ADDRESS_177562] substantial safet y and efficacy 
limitations. The drugs currentl y approved for use as adjunctive therap y to antidepressants for the 
treatment of MDD —namely , the at ypi[INVESTIGATOR_153869] ® (aripi[INVESTIGATOR_4253]), Seroquel XR® 
(quetiapi[INVESTIGATOR_123111]), and Rexulti® (brexpi[INVESTIGATOR_4253])—are associated with significant adverse 
reactions, as well as a number of serious warnings and precautions. Originally  developed for the 
treatment of ps ychotic disorders, these drugs share a number of clinicall y relevant adverse effects 
based on their mechanisms of action. 
Naurex, Inc 16
RAP- MD-01 Protocol Amendment 3 07 Dec 2018As all current antipsy chotic agents modulate central dopaminergic s ystems, they  all carry  a risk 
of extrapy ramidal s ymptoms such as muscular rigidity , acute dy stonia, as well as akathisia, 
which is a particularly  
relevant adverse event (AE) that complicates clinical management in a 
significant number of treated individuals, as high as 45% ( Sachdev, 1995). In addition, these 
compounds
are associated with a risk of neuroleptic malignant s yndrome andtardive d yskinesia. 
Depending on their individual pharmacological profile, antipsy chotics also carry  a risk for
metabolic changes including h ypergl ycemia/diabetes mellitus, dy slipi[INVESTIGATOR_153870]; blood d yskrasias such as leucopenia, neutropenia, and agranulocy tosis; orthostatic 
hypotension; cognitive and motor impairment; cataracts; and insomnia ( Abilify , 2014; Seroquel, 
2013; 
Rexulti, 2015
). The range of clinicall y relevant side effects with antips ychotics has to be 
balanced carefull y against the potential for therapeutic benefit s in patients with major depression. 
In this context it is important to highlight that for the approved at ypi[INVESTIGATOR_153871] y adjunctive dosing to become apparent , and in 
many  subjects, adverse effects occurred substantially  earlier than the mood -alleviating effects of 
these drugs . 
Furthermore, the drugs currentl y approved for adjunctive treatment of MDD also have limited 
efficacy . The pi[INVESTIGATOR_153872] , the at ypi[INVESTIGATOR_153873], showed a delay ed onset of effect (1 -2weeks), a modest magnitude 
of effect (effect sizes were 0.35 -0.39 after 6 weeks of repeat dosing) and modest rates of 
response and remission after 6 weeks of repeat dosi ng (response rates were 32 -34% and 
remission rates were 25- 26%) ( Berman et al, 2007; Marcus et al, 2008 ). 
Clearly , there is a substantial need for the development of novel treatments with a better 
safet y/tolerability  profile and a faster onset of full therapeutic benefit . Rapastinel has initially  
shown substantially  improved safet y/tolerability  as well as 
promising efficacy , in both speed of 
onset and overall magnitude, for adjunctive therapy  in MDD. 
Rapastinel as a N ovel Approach to Major Depressive Disorder Treatment
The mechanism of action of rapastinel is entirel y different from that of at ypi[INVESTIGATOR_34922].
Rapastinel is a n N-methyl -D-aspartate receptor (NMDAR) modul atorwith a novel and complex 
pharmacological mechanism of action, acting as a nonselective agent at NR2 subunits and 
display ing properties as a functional partial agonist in a number of pharmacological assay s. 
Rapastinel has demonstrated antidepressant p roperties in relevant animal models, display s 
cognitive enhanc ing properties in treated animals, and facilitates hippocampal long -term 
potentiation (L TP) of s ynaptic transmission in preclinical models. In contrast to ketamine, no 
signal of abuse liability  was detected in informative animal models. 
Naurex, Inc 17
RAP- MD-01 Protocol Amendment 3 07 Dec 2018Rapastinel is available as an intravenous (IV) formulation only . In 2Phase 2 clinical studies in 
patients with MDD, single IV doses of rapastinel 5 mg/kg and 10 mg/kg have been shown to 
produce marked antidepressant effects within 1 day  that lasted for approximately 1 week or 
longer in responding patients. These antidepressant effects are very  similar to ketamine’s effects 
when administered at a low dose as an infusion . In a systematic review and meta -analysis of 
ketamine and other NMDAR antagonists in the treatment of major depression, a single infusion 
of ketamine produced a rapid, y et transient antidepressant effect, accompanied by  [CONTACT_153883] e effects (Newport et al, 2015 ). 
The available Phase [ADDRESS_177563] a partial response to ADT.
Efficacy Objectives
Primary  efficacy  objective: To evaluate the efficacy  of rapastinel ( 450mgIV) versu s placebo 
in the treatment of MDD as an adjunct to ongoing ADT, as measured b y the change from 
baseline to end of stud yin theMontgomery -Åsberg Depression Rating Scale ( MADRS )total 
score .
Key secon dary efficacy  objective: To evaluate the efficacy  of rapastinel ( 450mgIV) versus
placebo in the treatment of MDD as an adjunct to ongoing ADT, as measured by  [CONTACT_153884] [ADDRESS_177564] dose of treatment.
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc 19
RAP- MD-01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc 20
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].0 INVESTIGATIONAL PLAN
9.1 OVERALL STUDY DESIGN AND PLAN: DESCRIPTIO N
This study  is a multicenter, randomized, double- blind, placebo -controlled, parallel -group, [ADDRESS_177565] a partial response to ADT. The study  will include a 
total of 12 visits and will be approximately  4 to 6 weeks in duration ( Figure 9.1.3–1): 
Up to
2-week screening period 
3-week double -blind treatment period 
1-week safet y follow -up period (for patients who do not enter the RAP -MD-04 maintenance 
study )
9.1.1 Screening Period
After providing written consent, patients will enter a screening period of up to 14 day s.The 
screening/washout period will be up to 2 weeks prior to Visit 2. Screening procedures may  be 
conducted on up to 2 separate dates where necessary  to accommodate patient and 
study  center
schedule ; however, every effort should be made to conduct all procedures as earl y as possible in 
the screening period and the rater -administered MADRS and computer- administered MADRS 
must be collected on the same date. Patients will not receive any  investigational product ( IP)
during the screening period but must continue their background ADT at the same dose. Patients 
meeting the eligibility  criteria at the end of Visit 2 (Baseline) will be assigned a treatment by  [CONTACT_153885] (IWRS) and enter the double -blind treatment period.
9.1.2 Double -blind Treatment Period
Approximately  460 patients are planned for enrollment in the double -blind treatment period ( 230
patients each in the rapastinel 450 mg and placebo groups). Patients will be randomized in a ratio 
of 1:1 to 1 of 2 treatment groups: rapastinel 450 mg IV weekly  or placebo IV weekl y (both 
adjunctive to ongoing ADT). 
During the double -blind treatment period, patients wi ll have 3 study  visits per week. The visits 
willoccur in the following pattern: treatment day, 1 day  following the treatment day , 4 day s 
following the treatment day , and 7 day s following the treatment day  (which is the next treatment 
day). If necessary , study  visits may  be conducted up to 2 day s before or after the scheduled visits 
with the ex ception of visits thatare 24 hours apart (eg,Visits [ADDRESS_177566] be conducted 1 day  
apart ; similarly , Visits [ADDRESS_177567] be conducted 1 day  apart ) .All 
patients who receive IP must complete Visit 11. Upon completion of the double -blind treatment 
period , patients are eligible to enter the RAP -MD-04 maintenance stud y.Patients who do not 
enter RAP -MD-04 will enter a 1-week safet y follow -up period.
Naurex, Inc 21
RAP-MD- 01 Protocol Amendment 3 07 Dec [ZIP_CODE].1.3 Safety Follow -up Period
Patients who do not enter the RAP -MD- 04 maintenance stud y upon completing the double -blind 
treatment period and patients who prematurely discontinue from the stud y before completing 3 
weeks of double -blind treatment should enter the 1 -week safet y follow -up period. 
Additional follow -up visits may  be scheduled w ithin 30 day s, if necessary  for safet y reasons.
A schematic of the study  design is presented in Figure 9.1.3 –1. The Schedule of Evaluations is 
provided in Section 2.0and d etailed descriptions of each stud y visit can be found in 
Section 9.5.6.

Naurex, Inc 22
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].2 DISCUSSION OF STUDY DESIGN, INCLUDING TH E CHOICE OF 
CONTROL GROUPS
This multic enter, randomized, pla cebo -controlled, parallel -group study  with a 3 -week double -
blind treatment period, was designed based on prior studies that established rapastinel efficacy  
and safet y in adult patients with MDD. I n this study , investigators will enrol l patients 18 through 
65 years of age who me et the Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition ( DSM -5) criteria for MDD (American Psychiatric Association, 2013 ). The MDD 
diagnosis will be confirmed using the Modified Structured Clinical Interview for Diagnostic 
Statistic Manual of Mental Health Disorders, Fifth Edition (SCID) . The s ymptoms and severity 
of MDD will be assessed using the MADRS (Section [IP_ADDRESS].1). 
Study  centers will have experience with the study  population and will be encouraged to apply  
available guidelines to minimize patient risk or distress. 
Dose selection information is presented in Section 9.4.6. The planned dosing regimen is based on 
experience from previous rapastinel studies. 
A placebo treatment group is included in the study to comply  with worldwide regulatory  
preferences ( Laughren, 2001; Gispen -de Wied et al, 2012
), since placebo -controlled superiority  
trials have been shown to be conducive to higher quality  studies and to provide more reliable 
outcomes ( Feifel, 2008; Laughren, 2001; Gispen -de Wied et al , 2012). Additionally , from a 
scientific point of view, randomized double -
blind comparisons v ersus placebo are needed to 
permit adequate evaluation of efficacy . Comparison to a placebo treatment is also of value for 
distinguishing disease manifestations from adverse reactions tothe IP (EMA guidance, 2013 ). 
Theuse of placebo in place of the standard therapy  should not cause irreversible health problems 
or extreme suffering (depression is recognized b y the FDA as a condition in which there is 
substantial improvement and variability  in placebo groups) ( FDA Guidance for Industry : E10, 
May 2001 ). 
In Stud y RAP -MD-01, safety  and efficacy  assessments are included at every visit to determine 
adequacy  of response, safety , and tolerability . In the event of insufficient therapeutic response or 
worsening of the patient’s initial condition, the I P should be discontinued and an alternative 
treatment will then be all owed (Section 9.4.13). An independent Data and Safety  Monitoring 
Board (DSMB) will evaluate safety  data during 
the study  (Section 9.8).
9.[ADDRESS_177568] meet the following criteria:
1. W ritten informed consent, obtained from the patient before the initiation of any  
study -specific procedures (Section 5.3) 
2.
Male or female outpatients, 18 to 65years of age
Naurex, Inc 23
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].Meet DSM -5 criteria for MDD (based on confirmation from the modified SCI D, with a 
current m ajor depressive epi[INVESTIGATOR_153864] [ADDRESS_177569] no more than partial response (< 50% improvement) to ongoing treatment with a 
protocol -
allowed ADT  
 
 
 
 
 
8. If female of childbearing potential, have a negative serum β-
human chorionic gonadotropin 
(β-hCG) pregnancy  test
9.3.2 Exclusion Criteria
Patients who meet an y of the following criteria will not be eligible to participate in the stu dy:
Exclusion criteria to be assessed at Screening (Visit 1)
Psychiatric and Treatment-Related Criteria
1.DSM -5–based diagnosis of an y disorder other than MDD that was the primary focus of 
treatment within 6 months before Visit 1. Comorbid generalized anxiety disorder, social 
anxiety  disorder, or specific phobias are acceptable provided they  play  a secondary  role in 
the balance of s ymptoms and are not the primary  driver of treatment decisions.
2.Lifetime history  of meeting DSM -5 criteria for:
a.Schizophrenia spectrum or other ps ychotic disorder

Naurex, Inc 24
RAP- MD-01 Protocol Amendment 3 07 Dec 2018b.Bipolar or related disorder
c.Major neurocognitive disorder 
d.Neurodevelopmental disorder of greater than mild severit y or of a severity 
that impacts the patient’s ability  to consent, follow study  directions, or 
otherwise safel y participate in the study
e.Dissociative disorder
f.Posttraumatic stress disorder
g.MDD with psy chotic features
 
 
 
 
 
 
 
 

Naurex, Inc 25
RAP- MD-01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
9.Suicide risk, as determined by  [CONTACT_44735]:
 
 
 
 
 
 
 

Naurex, Inc [ADDRESS_177570] ances , before the completion of the study  visits and 
procedures. Patients can be prematurel y discontinued from the stud y after careful consideration 
for one of the following reasons:
Screen failure (f ailure to meet inclusion/exclusion criteria)
Pregnancy
Withdrawal of consent 
AE
oAny patient may  be withdrawn due to AE at the discretion of the Investigator
oAny patient who meets any  of the following criteria at any  point during the study  
must be withdrawn from participation, due to AE srelated to suicide :
a)A suicide attempt
 
In the event that a patient is withdrawn for a suicide- related AE, the patient should be refe rred 
for additional treatment or hospi[INVESTIGATOR_059], as clinically  indicated, in addition to withdrawing the 
patient from the study .
Lack of efficacy
Protocol violation
Noncompliance with IP
Noncompliance with ADT
Lost to follow -up 
Study  terminated by  
[CONTACT_2728]
Study  center terminated by  [CONTACT_153886], Inc 28
RAP- MD-01 Protocol Amendment 3 07 Dec 2018Other 
All randomized patients who prematurely  discontinue from the study , regardless of cause, should 
beseen for a final assessment at an Earl y Termination (ET) Visit. A final assessment will be 
defined as compl etion of the evaluations scheduled for all patients at Visit 11. All patients 
discontinuing the study  prematurel y should enter the [ADDRESS_177571] be requested in writing to return to the study  center for a final assessment. A 
copy  of the letter, together with the source docume ntation, will be kept in the Investigator’s files. 
The reason for premature discontinuation from the study  will b e recorded on the Study  
Termination Page of the eCRF. Study  center staff will be contact[CONTACT_153887] d.
9.3.4 Patient Replacement Procedures
Patient s in this study  who prematurel y discontinue treatment will not be replaced.
9.4 TREATMENTS
Patients meeting the eligibility  criteria at the end of Visit 2 (Baseline) will be randomized in 
double -blind fashion to 1of 2treatment groups: placebo or rapast inel [ADDRESS_177572] enter the study  while h avingno more than partial response 
(<50% improvement) to ongoing treatment with a protocol -
allowed ADT   
 
 
 
 
 
 
 
Upon entry  into the study at Screening ( Visit 1 ),the dosage of the ADT must be held constant at 
a dose allowed in the respective label through Vis it 11/ET. I f a patient experiences an AE, 
intercurrent illness, or symptoms of intolerance, he or she will be permitted to stop taking the 
ADT for a maximum of [ADDRESS_177573] patients bring their background ADT 
toVisits 5, 8, and 11 for verification of patient
-reported compliance b y pi[INVESTIGATOR_692] (to the extent
possible).

Naurex, Inc 29
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].4.2 Treatments Administered
The IPwill only  be administered to eligible patient s by a medically  qualified person as per the 
local state regulations. The range of persons who can administer an IV can be a ph ysician, a 
physician assistant, nurse, or nurse practitioner, etc,depending on the local and/or state law.
IP should be administered after all efficacy  and safety  assessments with the exception of the 
postdose assessments described below. IP will be administered in a “slow bolus” injection to 
each stud y patient in an upper extremity  vein within approximately  
[ADDRESS_177574] be immediately  available and in close proximity  to the patient(s) to attend to 
medical emergencies. The study  center must have the capabilities, in accordance with the 
applicable country , local, and/or state regulations and stand ard of care, to resuscitate a patient in 
the event of a medical emergency .
The patient should not be discharged from the study center until the following are completed:
Postadministration vital sign measures (approximately  15 minutes after administration)
Patient is clinically  assessed and determined to not be at increased risk of suicidality in 
the opi[INVESTIGATOR_689] (or medically  qualified sub investigator)
Patient is assessed for mental status and is determined to be free of perceptual 
disturbances or other conditions that would deem them not read y for discharge from the 
study  center , in the opi[INVESTIGATOR_689] (or medically  qualified subinvestigator)
A phy sician licensed in the state (Investigator or subinvestigator) determines that they  are 
medically  able to leave the study  center and provides written signoff not less than 15 
minutes following administration (see IV Administration and Discharge Notes document 
in Program Reference Manual )
9.4.3 Identity of Investigat ional Products
Rapa stinel 450 mg IV Prefilled Sy ringes: 
 
Placebo rapastinel IV Prefilled Sy ringes: prefilled single -dose sy ringes for injection containing [ADDRESS_177575] be accounted for. In addition, a t the end of the study , all 
unused IPshould be returned to the Sponsor or the local distributor at the address provided in the 
Study  Reference Manual .
9.4.5 Method of Assigning Patient s to Treatment Groups
After a patient signs the ICF at Screening (Visit 1), study  personnel will register the patie nt in the 
IWRS, and the s ystem will assign the patient a sequential PI D.
 
 
his PI D 
number will be used to identify  the patient throughout the study  (ie, at all periods of the study ).
The I Pwill be labeled with me dication kit numbers. The IWRS will provide the study  center
with the specific medication kit number(s) for each randomized patient at the time of 
randomization. Study  centers will dispense IP according to the IWRS instructions. Study  centers
will also log onto the I WRS at subsequent visits to obtain a study  medication kit number for 
dispensing the IP. Study  centers will receive the IWRS confirmation no tifications for each 
trans action. All notifications are to be maintained with the study  source documents.

Naurex, Inc 31
RAP-MD- 01 Protocol Amendment 3 07 Dec [ZIP_CODE].4.6 Selection of Dos ages in the Study
The dose of rapastinel in this study  was selected based on 2Phase 2 clinical studies in patients 
with MDD, in which single IV doses of rapastinel 5 mg/kg and 10 mg/kg were shown to produce 
marked antidepressant effects within [ADDRESS_177576] patients as t his represents a dose of 
4.5 mg/kg in a 100 kg patient and a dose of 9 mg/kg in a 50 kg patient.
9.4.7 Selection and Timing of Dose for Each Patie nt
The I Pwill be administered IV using the assigned single -use prefilled sy ringes at Visits 2, 5,and 
8.
Screening Period [IP_ADDRESS]
At Screening (Visit 1) after written consent is obtained, patient s enter a screening period of up to 
14 day s. No I P is administe red during the screening period; however, patients must continue 
their background ADT at a stable dose.
Double -blind Treatment Period [IP_ADDRESS]
Patients who meet all eligibility  criteria at Screening (Visit 1) and who continue to meet all the 
eligibility  criteria for participation in the study  at the Baseline Visit (Visit 2) will be assigned an 
IP kit number via IWRS at Baseline ( Visit 2). Patients will receive the first dose of IP that day . 
The I P kit numbers will also be assigned by  [CONTACT_153888] (ie, Visits 5 and 
8).
Patients will receive either rapastinel 450 mg or placebo from a prefilled single -dose sy ringe at 
Visits 2, 5, and 8. 
Safety Follow -up Period [IP_ADDRESS]
Patients who complete 3 weeks of randomized treatment are eligible to enter the RAP -MD- 04 
maintenance stud y. If they do not enter RAP -MD- 04, they should enter the safet y follow -up 
period. Patients who di scontinue the study  prematurely  should enter the safety  follow -up period. 
No IP is administered during the safet y follow -up period and patients’ background ADT may  be 
modified as deemed appropriate b y the Investigator.
9.4.[ADDRESS_177577] of patient randomizat ion codes will be generated b y Statistical Programming and 
implemented by  [CONTACT_153889] (an electronic version will be stored on a secure server). This 
list will identify each patient by  [CONTACT_153890]’s corresponding 
treatm ent assignment.
Naurex, Inc [ADDRESS_177578] notify  
the Study Physician immediatel y (refer to Appendix II) and a full written explanation must be 
provided if the blind is broken. Before IPis unblinded, every  attempt should be made to discuss 
the case with the Study Physician. Breaking the code at the study center will immediately 
disqualify  the patient from further participation in the study .
Treatment codes may  be broken b y Global Drug Safet y for regulatory repor ting purposes. In 
such cases, the study  staff will be kept blinded and the patient will not need to be disqualified 
from the study .
For IWRS Unblinding
In an emergency , the Investigator can obtain the treatment assignment of any patient at his or her 
study center through the IWRS. The Investigator will access the IWRS to break the blind and 
record the unblinding in the eCRF .
9.4.[ADDRESS_177579] of example medications that are allowed and not allowed as concomitant medications for 
either epi[INVESTIGATOR_153874] . Medication history  (psy chotropic 
medication history  during the previous [ADDRESS_177580] 12 
months) will be recorded at Screening (Visit 1) in the eCRF. Thereafter, any changes in 
concomitant medications or an y new medications added will be recorded in the eCRF.
 
 
 
 
 
 
 

Naurex, Inc 33
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018Zolpi[INVESTIGATOR_153875], Inc 34
RAP-MD- 01 Protocol Amendment 3 07 Dec [ZIP_CODE].4.11 Other Restrictions
Alcohol [IP_ADDRESS]
It is recommended that p atients abstain from alcohol consumption during the study .
Contracept ion [IP_ADDRESS]
For purposes of this study, females will be conside red of childbearing potential unless they  are 
naturally  postmenopausal or permanentl y sterilized (ie, hy sterectomy ). Natural menopause is 
defined as the permanent cessation of menstrual periods, determined retrospectivel y after a 
woman has experienced 12 months of amenorrhea without any other obvious pathological or 
physiological cause . 
For women of childbearing potential and male partners of childbearing potential who may  
participate in the stud y, the following methods of contraception, if properl y used, are generally  
considered reliable: hormonal contraceptives (ie, oral, patch, injection, implant), male condom 
with intravaginal spermicide, diaphragm or cervical cap with spermicide, vaginal contraceptive 
ring, intrauterine device, surgical sterilization (bilateral tubal ligation, bilateral salpi[INVESTIGATOR_8820] y), 
vasectomized partner, or sexual abstinence.
The I nvestigator and each patient will determine the appropriate method of contraception for the 
patient during the participation in the study .
SeeSection [IP_ADDRESS] for pregnancy  reporting procedures .
9.4.[ADDRESS_177581] patients bring their background ADT 
to Visits 5, 8, and 11 for verification of patient -reported compliance b y pi[INVESTIGATOR_692] (to the extent 
possible). Missed doses or other changes in the dose of ADT and the reason should be captured 
in the eCRF.
9.4.13 Treatment After Discontinuation
Patients whose MDD symptoms worsen or are determined by [CONTACT_153891] y controlled prior to completing the double -blind treatment period will be allowed to 
discontinue the study  and start appropriate treatment at the I nvestigator’s discretion. This new 
treatment will not be provided by  [CONTACT_1034]. Patients who initiate a new treatment must be 
discontinued from the study .
Naurex, Inc 35
RAP-MD- 01 Protocol Amendment 3 07 Dec [ZIP_CODE].5 EFFICACY AND SAFETY VARIABLES
9.5.1 Diagnostic and Efficacy Assessments
Diagnostic Assessments [IP_ADDRESS]
The SCI D will be administered during the screening interviews b y a ps ychiatrist, doctoral level 
clinical psy chologist ,or other clinician who has extensive professiona l training and experience in 
the diagnosis of mental illness and who meets the training requirements and qualifications 
standards set b y the Sponsor and rater training vendor.
Patients will complete a computer -administered Diagnostic Validation (DxV) asse ssment at the 
Screening visit prior to the rater -administered SCID, on a tablet computer provided to the study  
center. The DxV will collect data about the patients’ history  relative to lifelong history  of MDD. 
The patient’s diagnostic information, based on the responses to the computerized interview, will 
be reviewed b y the independent clinical reviewers team appointed b y the Sponsor, and an y 
uncertaint y raised b y the patient’s responses on the diagnostic interview will be discussed with 
the Investigator/st udy center clinician in order to establish confidence in the diagnosis. Patients 
for whom diagnostic agreement between the Investigator/study center clinician and the rater 
vendor clinician cannot be reached, may  not be appropriate for study  participation.
 
 
 
 
 
Efficacy Assessment s [IP_ADDRESS]
The efficacy  assessments (MADRS will be administered by a psy chiatrist, doctoral 
level clinical ps ychologist, or other clinician who has extensive professional training and 
experience in the diagnosis of mental illness and who meets the training requirements and 
qualifications standards set by  [CONTACT_153892].
[IP_ADDRESS].1 The Montgomery -Åsberg Depression Rating Scale
The MADRS ( Montgomery  and Åsberg, 1979 ) is a clinician -rated scale. The MADRS will be 
used to assess depressive sy mptomatology . Patients are rated on [ADDRESS_177582]. Each item will be scored on a 
7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates 
symptoms of maximum severit y. 

Naurex, Inc 36
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018A qualified rater (ie, who meets the training require ments and qualifications set by  [CONTACT_153893] )at each investigational center will conduct the MADRS assessment. The rater -
administered MADRS will be used for analyses. In addition to MADRS administration by  a 
qualified rater, each patient will complete an interactive, 
computer -administered MADRS interview on the dedicated study  device. Data from the 
computer -administered interview will be compared with data derived from the 
rater-administered interview on an ongoing basis as part of a rem ote qualit y assurance program 
conducted b y an indep endent vendor appointed b y the S ponsor. 
At each visit with a MADRS assessment, the rater -admin istered MADRS interview will be audio 
recorded. The computer -administered interview will involve a series of p robe and follow -up 
questions with multiple -choice response options. At the S creening V isit, the computer 
administered MADRS will be conducted prior to the r ater-administered MADRS. At all other 
visits, the rater -administered MADRS will be conducted first.
 
 
 
 
 
9.5.[ADDRESS_177583] be documented. The procedures discussed below will be 
completed at the designated visits.
Adverse Events [IP_ADDRESS]
An AE is an y untoward medical occurrence in a patient or clinical investigation patient 
administere d a pharmaceutical product and which does not necessarily  have to have a causal 
relationship with this treatment. An AE can therefore be an y unfavorable and unintended sign 
(including an abnormal laboratory  finding, for example), s ymptom, or disease tempor ally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product (ICH -E2A).
For the purpose softhe study  center’s data collection responsibilities , any  untoward event that 
was reported from the time the patient signed the ICFuntil [ADDRESS_177584] known dose of IP (if the final visit does not occur) is to be 
considered an AE.
Examples of AEs are as follows:
Changes in the general condition of the patient
Subject ive sy mptoms offered b y or elicited from the patient

Naurex, Inc 37
RAP- MD-01 Protocol Amendment 3 07 Dec 2018Objective signs observed by  [CONTACT_153894]
All diseases that occur after signing inform edconsent, including an y change in severit y or 
frequency  of pre -existing disease
All clinically  relevant abnormalities in laboratory  values or clinicall y relevant physical 
findings that occur during the stud y schedule
Please note that medical procedures scheduled prior to consenting but occurring during the study  
should not be capture das AEs ,but should be listed in the medical history  if related to a pre -
existing condition .
[IP_ADDRESS].[ADDRESS_177585] be recorded on the appropriate AE reporting page of the patient’s 
eCRF. Causal relationship must be assessed b y answering the following question:
Is there a reasonable possibility  the IPcaused the event?
Yes: There is evidence to suggest a causal relationship between the IPand AE, ie: 
There is a reasonable temporal relationship between the IPand the event, and/or 
The event is unlikel y to be attributed to underl ying/concurrent disease or other 
factors, and/or
Positive dechallenge and/or rechallenge exist
No: There is no evi dence to suggest a causal relationship between the IPand AE, ie :
There is no reasonable temporal relationship between the IPand the event, or
The patient did not take the IP, or
The event is likel y to be attributed to underl ying/concurrent disease or other factors, 
or
The event is commonl y occurring in the (stud y) population independent of IP
exposure
[IP_ADDRESS].2 Severity Assessment
The Investigator will provide an assessment of the severit y of each AE b y recording a severit y 
rating on the appropriate AE reporting page of the patient’s eCRF. Severity, which is a 
description of the intensity of manifestation of the AE, is distinct from seriousness, which 
implies a patient outcome or AE -required treatment measure associated with a threat to life or 
functionality  (Section [IP_ADDRESS].3). Severit y will be assessed according to the following scale:
Naurex, Inc 38
RAP- MD-01 Protocol Amendment 3 07 Dec 2018Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate :A type of AEthat is usually  alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily  living, causing 
discomfort , but poses no significant or permanent risk of harm to the research 
participant.
Severe: A type of AEthat interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
[IP_ADDRESS].[ADDRESS_177586] medical occurrence that at any  dose:
Results in death
Is life threatening
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity , or
Is a congenital anomal y/birth defect
Important medical events that may  not result in deat h, be life threatening, or require 
hospi[INVESTIGATOR_44719], based on appropriate medical judgment, they  
may jeopardize the patient and may  require medical or surgical intervention to prevent one of the 
outcomes listed in this definit ion. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency  room or at home, blood dy scrasias 
or convulsions that do not result in patient hospi[INVESTIGATOR_059], or the development of IPdependency  
or drug abuse.
Emergency  room visits that do not result in hospi[INVESTIGATOR_153876].
Preplanned hospi[INVESTIGATOR_602] ( eg, elective procedures for pre -existing conditions that did not 
worsen, such as cosmetic surgery  and h ysterectomy ) are excluded from SAE reporting.
[IP_ADDRESS].[ADDRESS_177587] occurred since the 
previous visit. Pat ients will be asked to volunteer information with a nonleading question such 
as, “How do you feel since your last visit?” Study  center personnel will record all pertinent 
information in the patient’s eCRF. 
All AEs must be recorded on the appropriate AE re
porting page of the patient’s eCRF whether or 
not they  are considered causally  related to the IP.
Naurex, Inc [ADDRESS_177588]:
Provide an assessment of the seriousness of the event ( ie, is it an SAE?), as well as the 
severit y and casual relationshi p
Document all actions taken with regard to the IP
Detail an y other treatment measures taken for the AE
Document the outcome of the AE
In addition, patients are to be reminded, as described in the I CF and in accordance with Section 
[IP_ADDRESS], to notify  study  center personnel of any AEs occurring during the [ADDRESS_177589] study  
period. An y AEs reported by [CONTACT_102] (or patient representative) during this period are to be 
recorded in original source documents. AEs are also to be recorded in the eCRF if at least one of 
the following condition sismet: 1) the event meets the criteria for an SAE (see Sections [IP_ADDRESS].3
and [IP_ADDRESS].4), and/or 2) the event is judged b y the Investigator to be potentially  causall y related 
to IP.
Any AEs that are ongoing at the time of the final protocol -defined stud y visit will be followed 
until the condition returns to prestudy status, has resolved or stabilized, or can be explained as 
being unrelated to the IP. If a follow -up visit is deemed necessary  for appropriate safety  
surveillance, it will take place within [ADDRESS_177590] [IP_ADDRESS]
The Sponsor is required to inform worldwide regulatory  authorities of SAEs that meet specific 
criteria. Therefore, the Sponsor must be notified immediately  regardi ng any  SAE that occurs 
after informed consent is obtained.
Within [ADDRESS_177591] be recorded on the 
appropriate pages of the patient’s eCRF. All SAEs are to be followed b y the st udy staff until 
resolution or until the SAE is deemed stable. The Sponsor may  contact [CONTACT_153895].
Fax the SAE Form for Clinical Trials to the Sponsor .
Reporting of Pregnancies Occurring During the Study [IP_ADDRESS]
Study  center personnel must report every  pregnancy  from the time the patient signs the ICF until 
[ADDRESS_177592] report the event to Global Drug Safety on the Clinical Trial Pregnancy Form and 
fax it to the SAE/ Pregnancy fax number provided in Section [IP_ADDRESS] , even if no AE has occurred. 
Pregnancies in female partners of male patients occurring during the time frame described above 
must also be reported. 

Naurex, Inc 41
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018Any pregnancy  of a patient treated with IP(or in female partners of male patients occurring 
during the timeframe described above) must be followed to term and the outcome reported b y 
completing a follow -up Clinical Trial Pregnancy  Form. If the pregnancy  is associated with an 
SAE (eg, if the mother is hospi[INVESTIGATOR_143460]), a separate SAE Form for Clinical Trials 
must be filed as described in Section [IP_ADDRESS] , with the appropriate serious criterion (eg, 
hospi[INVESTIGATOR_059]) indicated in addition to the pregnancy  form.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc [ADDRESS_177593] 3 study  visits per week .The visits occur in the 
following pattern: treatment day , 1 day  follow ing the treatment day , 4 day s following the 
treatment day , and 7 days following the treatment day  (which is the next treatment day ).If 
necessary , study  visits may  be conducted up to 2 days before or after the scheduled visits with 
the exception of visits that are 24 hours apart (ie, Visits [ADDRESS_177594] be conducted 1 day  apart ; 
similarly ,Visits [ADDRESS_177595] be conducted 1 day  apart) . Upon 
completion of the double -blind treatment period ,patients are eligible to enter the RAP -MD-0 4 
maint enance study or enter a 1 -week safety follow -up period.

Naurex, Inc 47
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
 
 

Naurex, Inc 48
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 

Naurex, Inc 49
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 

Naurex, Inc 50
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
 
 

Naurex, Inc 51
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 

Naurex, Inc 52
RAP- MD-01 Protocol Amendment 3 07 Dec 2018 
 

Naurex, Inc 53
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 

Naurex, Inc 54
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
 
 

Naurex, Inc 55
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
Unscheduled Visits [IP_ADDRESS]
Unscheduled visits can be performed if safet y concerns arise and at the discretion of the 
Investigator. Addit ional examinations may  be performed as necessary  to ensure the safet y and 
well-being of the patients during the stud y.
9.6 DATA QUALITY ASSURAN CE
9.6.1 Data Monitoring
Before an y patient enters the study , a representative of the Sponsor will meet with the 
Investigat or and the study  center staff to review the procedures to be followed during the stud y. 
Electronic data capture (EDC) functionality training is provided via computer -based training to 
train investigators and authorized designees on recording the data in th e eCRFs using the EDC 
system. After the first patient is enrolled, the Sponsor representative, a Regional Site Manager or 
designee , will periodically  monitor the progress of the study  by [CONTACT_143505] -site visits. This 
Regional Site Manager or designee wil l review query  statuses remotel y, possibly  warranting 
more frequent communication and/or study  center visits with the Investigator and the study  
center staff. The Investigator will make available to the Regional Site Manager or designee 
source documents (w ritten notes and electronic medical records, if used), signed consent forms, 
and all other stud y-related documents. The Investigator and the stud y center staff will be 
responsible for data entry of patient data into the eCRFs via the EDC system, resolving data 
queries generated via the EDC sy stem and providing missing or corrected data. The Investigator 
or designee will be responsible for approving all changes performed on the data, and endorsing 
the patient data within the EDC system. This approval method will include apply ing an 
electronic signature [CONTACT_153914] a uniquely assigned username [CONTACT_153915] a traditional handwritten signature [CONTACT_153916].
9.6.[ADDRESS_177596] access. Patient’s data are to be entered into the EDC sy stem by  [CONTACT_153896]. After data entry into the EDC system by [CONTACT_153897], a combination of manual and programmatic edit checks will be used to review the 
data for completeness, logic, and adherence to study protocol. As a result of these edit checks, 
data monitoring ,and reviews ,queries may  be electronically  issued to the study  center and should 
be answered electronically via the EDC system.

Naurex, Inc 56
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018Each query  will carry  identify ing information (assigned username, date ,and time) to assist the 
Sponsor and the I nvestigator on the origin of the data clarification request and the resp onse 
provided b y the Investigator. All data changes made to the patient’s data via a data query  will be 
approved b y the Investigator prior to final database lock.
After all data have been reviewed and all issues have been resolved, the database will be loc ked.
All data collected in the context of this study will be stored and evaluated per regulatory  
requirements and applicable guidance for electronic records. Also, data will be stored and 
evaluated in such a way  as to guarantee patient confidentiality  in accordance with the legal 
stipulations apply ing to confidentiality  of data. Study  records ( eg, copi[INVESTIGATOR_1495], laboratory  
reports, regulatory  documents) will be retained at the study  center , along with adequate source 
documentation, according to FDA and I CH requirements. All study  records must be available for 
inspection by [CONTACT_1034], its authorized representatives, the FDA ,or other health authorities.
 
 
 Source documents will be used at the study  centers and 
may include a patient’s medical record, hospi [INVESTIGATOR_1332], clinic charts, the I nvestigator’s patie nt 
study  files, as well as the results of diagnostic tests such as laboratory  tests, ECGs ,etc. 
Acentralized clinical laboratory  will be used for the anal ysis of all blood samples. Additional 
information on the collection and handling of samples is detail ed in the Lab Procedure Manual.
9.7 STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE
9.7.1 Analysis Populations
Three populations will be considered in the statistical anal ysis of the stud y,as specified in the 
following subsections.
Enrolled Population [IP_ADDRESS]
The Enrolled Population will consist of all patient s who sign informed consent ,receive a patient 
identification number (PID)number ,andenter into screening .
Safety Population [IP_ADDRESS]
The Safet y Population will consist of all patients who receive at least 1 dose of randomized IP.
Modified Intent -to-Treat Population [IP_ADDRESS]
The modified Intent -to-Treat ( mITT) Population will consist of all patients who arerandomized, 
receive at least [ADDRESS_177597] 1 postbaseline assessment of the MADRS total 
score. 

Naurex, Inc 57
RAP-MD- 01 Protocol Amendment 3 07 Dec [ZIP_CODE].7.2 Patient Disposition
The number and percentage of patients in theEnrolled , Safety , and mITTpopulations will be 
summarized by  [CONTACT_44747].
Screen -failure patients (ie, patients screened but not included in the Enrolled Population ) and the 
associated reasons for failure will be tabulated overall for all screened patients . 
The number and percentage of patients in the mITT Population who complete the double -blind 
treatment period and ofpatients who prematurely  discontinue during the same period will be 
presented for each treatment group and pooled across treatment groups . The reasons for 
premature discontinuation during the double -blind treatment period as recorded on the 
disposition pages of the eCRFs will be summarized by  [CONTACT_153898].
9.7.3 Demographics and Other Baseline Characteristics
Demographic parameters ( eg, age, race, ethnicit y, sex, weight, height, body mass index ) and 
other baseline characteristics wi ll be summarized by  [CONTACT_44748] y and mITT 
populations. 
9.7.4 Extent of Exposure and Treatment Compliance
Extent of Exposure [IP_ADDRESS]
Patients in the Safety  Population will be categorized by  [CONTACT_153899]. The 
number and percent ageof patients in each category  will be summarized by  [CONTACT_1570]. 
Prior medication is defined as an y medication taken before the date of the first dose of 
randomized IP. Concomitant medication is defined as an y medication taken on or after the date 
of the first dose of IP. 
Both prior and concomitant medication use will be summarized by [CONTACT_153900]. Multiple medication use b y apatient will only  be counted once.
IV administration notes including site reaction at placement of IV, reaction to adhesive, infusion 
interruption, failure of administration device, increase in suicidality based on clinical evaluation, 
and perceptual dist urbance based on mental status assessment are collected. For each item, the 
number and percentage of patients who had a ‘y es’ response will be summarized by  [CONTACT_153901]. The number and percentage of patients taking e ach 
qualify ing ADT will be summarized by  [CONTACT_153898]. Mean daily  
dose foreach qualify ing ADT will be summarized using descriptive statistics (number of 
patients, mean, standard deviation [ SD], median, Q1, Q3, minimum, and maxim um) by  [CONTACT_153902] m ITTPopulation.
Naurex, Inc 58
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018Measurement of Treatment Compliance [IP_ADDRESS]
Dosing compliance for the background ADT during a specified period is defined as the total 
daily  dose administered to a patient during that period divided by  [CONTACT_153903]  100, as captured in the eCRF . Descriptive statistics for 
ADT compliance will be presented for each ADT and overall by [CONTACT_153904].
9.7.[ADDRESS_177598] 
dose of randomized treatment . All statistical hy pothesis tests will be performed at the 2 -sided 5% 
significance level for main effects. All confidence intervals (CIs) will be 2 -sided 95% CI s, unless 
stated otherwise.
For efficacy  analy ses in which study  center is a factor, a small center will be defined as a center 
with < 2 patients in ≥ 1 treatment group in the mITT Population. Small centers will be pooled to 
form pseudo -centers so that each treatment group includes ≥ 2 mITT patients within the center. 
Details of the pooling algorithm will be provided in the Statistical Analy sis Plan ( SAP).
Primary Efficacy Parameter [IP_ADDRESS]
The primary  efficacy  parameter will be the change from baseline in MADRS total score at end of 
study . The primary  analysis will be performe d using a mixed -effects model for repeated 
measures (MMRM ) with treatment group , pooled study  center, visit and randomized treatment -
by-visit interaction as the fixed effects, and baseline MARDS total score and baseline MADRS 
total score -by-visit interaction as covariates. An unstructured covariance matrix will be used to 
model the covari ance of within -patient scores. The Kenward -Roger approximation will be used 
to esti mate the denominator degrees of freedom ( Kenward et al, 1997; Kenward et al ,2003 ).The 
treatment difference for rapastinel versus placebo will be estimated and reported along with the 
corresponding 95% CI and nominal p-value.
In the case that the MMRM model with unstructured covariance fails to converge with the 
default algorithm, then the Fisher scoring algorithm will be used to provide better initial values 
of the covariance parameters; if the model still does not con verge, a simplified model without 
term for stud y center will be used to find the initial values of the covariance parameters. In the 
rare event that the model still does not converge after using those initial values, simplified 
covariance structures will b e used to fit the model in the following order: (1) ante -dependence, 
(2) heterogeneous autoregressive, 
(3) Toeplitz, and (4) compound sy mmetry .
Naurex, Inc 59
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018To assess the robustness of the primary MMRM results to the possible violation of the missing -
at-random assumpt ion, a sensitivity  anal ysis using a pattern -mixture model based on non -future 
dependent missing value restrictions ( Kenward et al, 2003 ) will be performed. The pattern for the 
pattern -mixture model will be defined b y the patient’s last visit with observed value. The 
observed MADRS total score at a visit is assumed to have a linear relationship with the patient’s 
prior measurements. The missing values will be imputed under the assumption that the 
distribution of the missi ng observations differs from the observed onl y by a shift parameter value 
Δ. The dataset with missing values will be anal yzed using the same model as the primary  
analysis for between -treatment group comparisons at the end of the treatment. The imputation o f 
missing values and the analy sis will be performed multiple times and the inference of this 
sensitivity  anal ysis will be based on the combined estimates using the standard multiple 
imputation technique. The values o fΔ will be selected as 0 to 8.
Key Secondary Efficacy Parameter [IP_ADDRESS]
The key  secondary  efficacy  parameter will be the change from baseline to 1day after the first dose 
of treatment in MADRS total score. This parameter will be anal yzed using the same MMRM as 
will be used for the primary  efficacy param eter.The treatment difference for rapastinel versus 
placebo will be estimated and reported along with the corresponding 95% CIand nominal p-
value.
A sequential testing procedure will be used to control the overall t ype I error rate at 
5% for the p rimary  andsecondary  efficacy  parameters. 
 
 
 
 
 
 

Naurex, Inc 60
RAP- MD-01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc 61
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 
Adverse Events [IP_ADDRESS]
All AEs will be coded b y system organ class and preferred term using the Medical Dictionary for 
Regulatory Activities .
An AE (classified b y preferred term) will be considered a treatment- emergent adverse event 
(TEAE) if it was notpresent before the first dose of I P or was present before the date of the first 
dose of IP and increased in severity  after the first dose of IP. An AE that becomes serious after 
the date of first dose of IP will also be considered as aTEAE. If more than [ADDRESS_177599] causalit y for the summarization by  [CONTACT_153905].
A serious adverse event (SAE )that occurred between the date of the first dose of IP and [ADDRESS_177600] dose of IP, inclusive, will be considered 
a treatment -emergent SAE (TESAE) . The number and percentage of patients who have 
on-therap y TESAEs will be summarized by [CONTACT_153906]. I n addition, the 
incidence of on -therapy  SAEs that leadto death will be summarized separatel y by [CONTACT_153907].
Overall summaries of AEs will be provided on a per -patient bas is for categori es of all TEAEs, 
treatment -related TEAEs, TESAEs, and TEAEs leading to stud y discontinuation.
 
 

Naurex, Inc 62
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc 63
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc 64
RAP- MD-01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.7.8 Interim Analysis
At the time of preparation for Protocol Amendment 2, a blinded interim analysis was 
performed as part of data quality review as the study was progressing. In this review, it 
was observed that the SDfor the primary and secondary endpoints were substantiall y 
lower than the originally assumed values for sample size calculations. The observed SDs in 
the blinded reviews of this study and other ongoing acute studies at the same time (RAP -
MD-02 and RAP -MD-03) were taken into consideration for revising the estimate of the 
sample size as proposed in the next section (Section 9.7.9 Determination of Sample Size) .
9.7.[ADDRESS_177601] deviation (SD) of 10 points, which provides 99% power to dete ct a 
difference of 3.[ADDRESS_177602] visit, Day 21, as recommended by [CONTACT_1622], 
EMA, and PDMA, and included in Amendment 2 of the protocol. At the same time of 
Amendment 2, a blinded data review was conducted for Studies RAP -MD-01, RAP -MD-02, 
and RAP -MD-03. The pooled SD for the 3 studi es were 7.4, 8.0, and 8.7, respectively, all 
smaller than the originally assumed 10 points. Sample size was re -calculated using 8.7 as the 
common SD. The calculation used MMRM model with simulations; it also assumed 
correlation of 0.5 between the repeated measures and an overall discontinuation rate of 15%. 
To have 90% power, the total sample size required is 360 patients. However, the study had 
already enrolled more than 440 patients with less than 5% of overall discontinuation rate, 
surpassing the re -estimated sample size of 360 patients. The study enrollment was halted as 
soon as operationally feasible. The final sample size is approximately 460 patients (230 
patients per treatment group).
9.7.10 Computer Methods
Statistical analy ses will be performed using version 9. 3 (or newer) of SAS .
9.[ADDRESS_177603]
The study  will be conducted under the supervision of an independent DSMB tobe chartered to 
review safet y data at predetermined points during the study .The DSMB may also decide to meet 
and review safet y data at other timepoints should it be deemed necessary .The DSMB is 
responsible for the ongoing review of safet y data in the clinical study and for making 
recommendations concerning the continuation, modification, and termination of the study  
(FDA Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data 
Monitoring Committees, March 2006 ).
All analy ses that are required to support the DSMB will be performed b y anindependent
unblinded statistician not otherwise involved in the study. Details of the DSMB membership, 
meeting schedule, and data review and anal ysis will be documented in the DSMB Charter.
9.[ADDRESS_177604] OF THE STUDY OR P LANNED 
ANALYSES
Any amendment to this protocol will be provided to the Investigator in writing by  [CONTACT_1034] . 
No protocol amendment may  be implemented (with the exceptions noted below) before it has 
been approved b y the IRB ,and the signature [CONTACT_3264], signed by  [CONTACT_737] , has been received 
by [CONTACT_1034] . If the protocol is amended to eliminate or reduce the risk to patients, the 
amendment may  be implemented before IRB review and approval. However, the IRB must be 
informed in writing of such an amendment, and approval must be obtained within reasonable 
time limits. 
Naurex, Inc 66
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].10 PROTOCOL DEVIATIONS
A protocol deviation is any  change, divergence, or departure from the study  design or procedures 
that is under the I nvestigator’s responsibility  and oversight (as defined by  [CONTACT_153908]) without 
prior written IRB approval or favorable opi[INVESTIGATOR_153877] a major impact on the patient’s rights, safety, or 
well-being, or on the integrit y and authenticity of the study data. Deviations may inclu de, but are 
not limited to, departure from inclusion/exclusion criteria, dosing, duration of treatment, failure 
to perform the required assessments at specified timepoints, scheduling of visits not in 
accordance with specifications, or patient safet y. Devi ating from the protocol is permitted only  if 
absolutely  necessary  for the safet y or clinical management of the patients and must immediately  
be reported to the Sponsor .
Asignificant protocol deviation is a form of protocol deviation that has a major impact on the 
patient’s rights, safet y, or well -being, or on the integrity  and authenticit y of the study data. The 
IRB must be notified within the time period dictated by [CONTACT_134874] . 
Naurex, Inc [ADDRESS_177605] to mutual agreement between the 
Investigator and the Sponsor and will follow the Sponsor’s Standard O perating P rocedure on 
publications.
Naurex, Inc [ADDRESS_177606] provide the following to the Sponsor before the start of the study :
A completed and signed Form FDA [ADDRESS_177607] be completed 
and returned to the 
Sponsor for submission to the FDA .
A fully  executed contract
The c urricul avitae for the Investigator and all subinvestigator s listed on Form FDA 1572, 
including a cop y of each physician’s license
A cop y of the original IRB approval for conducting the study . If the study is ongoing, 
renewals must be submitted at yearly intervals . All subsequent modifications must be 
submitted and approved by  [CONTACT_1201], as stated 
in Section 5.1.
A cop y of the IRB -approved ICF
A cop y of the H IPAA authorization f orm, or other local privacy applicable forms
A list of 
the IRB members or the US Department of Health and Human Services general 
assurance number
A cop y of the laboratory  certifications and reference ranges
The Investigator ’s Statement page in this protoco l,signed and dated b y the Investigator
Financial disclosure agreement completed and signed by  [CONTACT_153909] s listed on Form FDA 1572. The Investigator and all subinvestigator s will 
provide an updated financial disclosure agreement to the Sponsor [ADDRESS_177608] each 
patient’s use . All unused IPmust be 
returned to 
the Sponsor . 
11.[ADDRESS_177609] of this study , including eCRFs, source 
documents, consent forms, regulatory  documents, clinical laboratory  results, calibration logs, or 
reports (including, but not limited to, all local and central laborator y results and ECG reports), 
and medication inventory records in all formats (including, but not limited to, written, electronic, 
magnetic, and optical records, and scans, x -rays, and ECGs ) must be retained by  [CONTACT_153910] a period of at least [ADDRESS_177610] be notified in writing of the 
name [CONTACT_153917].
11.6 PATIENT CONFIDENTIALITY
All patient records will only  be identified by [CONTACT_44750][INVESTIGATOR_44723] . Patients’ names are not to 
be transmitted to the 
Sponsor . The Investigator will keep a m aster patient list on which the PID
number and the full name, address, and telephone number of each patient are listed.
Naurex, Inc 70
RAP- MD-01 Protocol Amendment 3 07 Dec 201812.0 INVESTIGATOR’S STATE MENT
I agree to conduct the study  in accordance with this protocol ( RAP -MD-01, Amendment 3, dated
07Dec2018) and with all applicable government regulations and good clinical practice 
guidance.
_______________________________________ _____/_____/______
Investigator ’s Signature [CONTACT_1782]
_______________________________________
Investigator ’s Name
[CONTACT_153918], Inc [ADDRESS_177611] include 
the following items:
A statement that the study involves research and an explanation of the purposes of the 
research; a description of the procedures to be followed and the 
identification of any  
procedures that are experimental; and the expected duration of the patient ’s parti cipation
A description of an y reasonably  foreseeable risks or discomforts to the patient
A description of an y benefits to the patient or to others that may  reasonably  be expected from 
the research. If the patient is to be paid for participating in the stud y, the consent form must 
state the amount that 
he/she will receive and the schedule of pay ment (to ensure neither 
coercion nor undue influence)
A disclosure of appropriate alternative procedures or courses of treatment, if an y, that might 
be advantageous to the 
patient
A statement describing the extent, if any , to which confidentiality  of records identify ing the 
patient will be maintained and noting the possibility  that the FDA, the Sponsor , the IRB , or 
an authorized contract research organization may  inspe ct the records
For research involving more than minimal risk, an explanation of whether any  medical 
treatment is available if injury  occurs and, if so, what it consists of or where further 
information may  be obtained
An explanation of whom to contact, incl uding the relevant telephone number, for answers to 
pertinent questions about the research and the research patient ’s rights and whom to contact 
[CONTACT_44751] a research -related injury  to the patient. (N ote: In some cases ,it may be 
necessary  to identify a person other than the Investigator as the contact . The guidance of the 
IRB may  be required)
A statement that participation is voluntary , that refusal to participate will involve no penalt y 
or loss of benefits to which the patient is otherwise entitled, and that the patient may 
discontinue participation at an
y time without penalty or loss of benefits to which the patient
is otherwise entitled
A statement that the particular treatment or procedures may  involve risks to the patient (or to 
the embry o or fetus if the patient is, or may  become, pregnant) that are at present 
unforeseeable
The e xpected circumstances forwhich the patient ’s participation may  be terminated by  [CONTACT_143507] ’s consent
Naurex, Inc 72
RAP- MD-01 Protocol Amendment 3 07 Dec 2018Any additional costs to the patient that may  result from participation in the research
The consequences of a patient’s decision to withdraw from the research and procedures for 
an orderl y termination of the patient ’s participation
A statement that signific ant new findings developed during the course of the research that 
may relate to the patient’s willingness to continue participation will be provided to the patient
The approximate number of patient s involved in the study
A statement of permission, providing consent for the patient to participate
(eg, “I agree to participate . . .”)
A place for the patient ’s signature [CONTACT_153919]
A statement indicating that information about this study  has been, or will be, entered into a 
databank that is pu blicly  accessible at www.ClinicalTrials.gov.
A cop y of the signed consent form must be given to the patient .
Naurex, Inc [ADDRESS_177612] information for the Sponsor personnel is maintained in the Study  Reference Manual.
Naurex, Inc 74
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 75
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 76
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 77
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 78
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 79
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 80
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 81
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 82
RAP- MD-01 Protocol Amendment 3 07 Dec 2018APPEND IX V. MONTGOMERY -ASBERG DEPRESSION RA TING SCALE
1. APPARENT SADNESS —Representing despondency , gloom and despair (more than just 
ordinary  transient low spi[INVESTIGATOR_2120]) reflected in speech, facial expression, and posture. Rate by  
[CONTACT_153911].
0No sadness.
[ADDRESS_177613] of the time.
5
6Looks miserable all the time. Extremely  despondent.
2.REPORTED SADNESS —Representing reports of depressed mood, regardless of whether it 
is reflected in appearance or not. I ncludes low spi[INVESTIGATOR_2120], despondency , or the feeling of being 
beyond help and without hope. Rate according to intensity , duration and the extent to which 
the mood is reported to be in fluenced b y events.
0Occasional sadness in keepi[INVESTIGATOR_153878].
1
2Sad or low but brightens up without difficulty .
3
4Pervasive feelings of sadness or gloominess. The mood is still influenced by  [CONTACT_153912].
5
6Continuous or un
varying sadness, misery  or despondency .
3INNER TENSION —Representing feelings of ill -defined discomfort, edginess, inner 
turmoil, mental tension mounting to either panic, dread, or anguish. Rate according to 
intensity , frequency , duration, and the extent o f reassurance called for.
0Placid. Only  fleeting inner tension.
1
2Occasional feelings of edginess and ill -defined discomfort.
3
4
Continuous feelings of inner tension or intermittent panic which the patient can onl y 
master with some difficulty .
5
6Unrelenting dread or anguish. Overwhelming panic.
Naurex, Inc 83
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].REDUCED SLEEP —Representing the experience of reduced duration or depth of sleep 
compared to the patient’s own normal pattern when well.
0Sleeps as usual.
[ADDRESS_177614] 2 hours.
5
6Less than 2or 3 hours sleep.
5.
REDUCED APPETITE —Representing the feeling of a loss of appetite compared with 
when well. Rate b y loss of desire for food or the need to force oneself to eat.
0
Normal or increased appetite.
1
2Slightly  reduced appetite.
3
4No appetite. Food is tasteless.
5
6 Needs persuasion to eat at all.
6.CONCENTRATION DIFFICULTIES —Representing difficulties in collecting one’s 
thoughts 
mounting to incapacitating lack of concentration. Rate according to intensity , 
frequency , and degree of incapacit y produced.
0No difficulties in concentrating.
1
2 Occasional difficulties in collecting one’s thoughts.
3
4Difficulties in concentrating a nd sustaining thought which reduces ability  to read or hold 
a conversation.
5
6Unable to read or converse without great difficulty.
Naurex, Inc 84
RAP- MD-01 Protocol Amendment 3 07 Dec [ZIP_CODE].LASSITUDE —Representing a difficulty getting started or slowness initiating and 
performing every day activities.
0Hardl yany difficulty getting started. No sluggishness.
1
2Difficulties in starting activities.
3
4Difficulties in starting simple routine activities which are carried out with effort.
5
6 Complete lassitude. Unable to do any thing without help.
8.INABILITY TO FEEL —Representing the subjective experience of reduced interest in the 
surroundings, or activities that normally  give pleasure. The abilit y to react with adequate 
emotion to circumstances or people is reduced.
0Normal interest in the surroundings and in other people.
[ADDRESS_177615] in the surroundings. Loss of feelings for friends and acquaintances.
5
6The experience of being emotionally  paral yzed, inability  to feel anger, grief or pleasure 
and a complete or even painful failure to feel for close relatives or friends.
9.PESSIMISTIC THOUGHTS —Representing thoughts of guilt, inferiority, self -reproach, 
sinfulness, remorse and ruin.
[ADDRESS_177616] and 
unshakable.
Naurex, Inc 85
RAP- MD-01 Protocol Amendment 3 07 Dec 201810.SUICIDAL THOUGHTS —Representing the feeling that life is not worth living, that a 
natural death would be welcome, suicidal thoughts, and preparations for suicide. Suicidal 
attempts should not in themselves influence the rating.
0Enjoy s life or takes it as it comes.
1
2Weary  of life. Onl y fleeting suicidal thoughts.
3
4Probably  better off dead. Suicidal thoughts are common, and suicide is considered as a 
possible solution, but without specific plans or intention.
5
6 Explicit plans for suic ide when there is an opportunity . Active preparations for suicide.
Naurex, Inc 86
RAP- MD-01 Protocol Amendment 3 07 Dec 2018 
 
 
 
 
 
 
 

Naurex, Inc 87
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 88
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 89
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 90
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 91
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 92
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 93
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 94
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 95
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 96
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 97
RAP- MD-01 Protocol Amendment 3 07 Dec 2018 

Naurex, Inc 98
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 99
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 100
RAP-MD- 01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 101
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 102
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 103
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 104
RAP- MD-01 Protocol Amendment 3 07 Dec 2018

Naurex, Inc 105
RAP- MD-01 Protocol Amendment 3 07 Dec 201814.0 LITERATURE CITED
Abilify  [package insert]. Toky o, Japan; Otsuka Pharmaceutical Co., L td. December 2014.
American Ps ychiatric Association (2013). Diagnostic and statistical manual of mental disorders : 
DSM -5. Washington, D C: American Ps ychiatric Association
Ashton AK, Jamerson BD, Weinstein W, et al. Antidepressant- related adverse effects impacting 
treatment compliance: Results of a patient survey . Current Therapeutic Research, Clinical and 
Experimental 2005;66(2):
96-106.doi:10.1016/j.curtheres.2005.04.006.
Berman RM, Marcus RN, Swanink R, et al
. The efficacy  and safety  of aripi[INVESTIGATOR_153879] y in major depressive disorder: a mu lticenter, randomized, double -blind, placebo -
controlled study . J Clin Psy chiatry  2007;68(6):843 - 53.
Boland RJ, Keller MB. Treatment of depression. In: Schatzberg AF, Nemeroff CB, editors. 
Essentials of clinical ps ychopharmacology. 2nd ed. Arlington, VA: American Psy chiatric 
Publishing, I nc.; 2006. p 465-78.
Bremner JD, Kry stal JH, Putnam FW, et al. Measurement of dissociative states with the 
Clinician Administered Dissociative States Scale (CADSS). J Trauma Stress 1998;11:125
–36.
EMA/CHMP/185423/2010 Rev. 2 previously  (CPMP/EWP/518/97, Rev. 1) Committee for 
Medicinal Products for Human Use (CHMP) 30 May 2013 Guideline on clinical investigation of 
medicinal products in the treatment of depression
Fava M, Davidson KG. Definition and epi[INVESTIGATOR_153880] -resistant depression. Psychiatr 
Clin No rth Am. 1996 Jun;19(2):179
-200.
FDA Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data 
Monitoring Committees, March 2006 
http://www.fda.gov/downloads/RegulatoryInformation/Guidan ces/ucm127073.pdf
FDA Guidance for Industry : Drug Induced L iver Injury -Pre-Marketing Clinical Evaluation ,July 
2009
FDA Guidance for Industry : E10, Choice of Control Group and Related Issues in Clinical Trials, 
May 2001
Feifel D. The use of placebo -controlled clinical trials for the approval of psy chiatric drugs: Part 
I—Statistics and the Case for the “Greater Good”. Psy chiatry  (Edgemont) 2008; 6(3)41 –43
Gispen
-de Wied C, Stoy anova V, Yu Y, et al. The placebo arm in clinical studies for treatment 
of Psy chiatric Disorders: A Regulatory  Dilemma. Eur Neurops ychopharmacol, 2012; 14 June 
(published ahead of print)
Naurex, Inc 106
RAP- MD-01 Protocol Amendment 3 07 Dec 2018Greenberg PE, Kessler RC, Birnbaum HG, et al . The economic burden of depression in the 
[LOCATION_002]: how did it change between 1990 and 2000? J Clin Psy chiatry  2003;64(12):[ADDRESS_177617];21(7):623-43.
Guy W: ECDEU Assessment Manual for Ps ychopharmacology -Revised, in (ed DHEW Publ No 
ADM 76 -338). Rockville, MD, U.S., U.S. Department of Health, Education, and Welfare, Public 
Health Service, Alcohol, Drug Abuse, a nd Mental Health Administration, NIMH 
Psychopharmacology  Research Branch, Division of Extramural Research Programs, 1976, pp 
218-222
Herdman M, Gudex C, Lloy d A, et al. Development and preliminary  testing of the new five
-level 
version of EQ -5D (EQ -5D-5L). Qual L ife Res. 2011 Dec; 20 (10):[ADDRESS_177618] MG, Molenberghs G, Thijs H. Pattern -mixture models with proper time dependence. 
Biometrika 2003; 90(1): 53-[ADDRESS_177619] MG, Roger JH. Small sample inference for fixed effects from restricted maximum 
likelihood . Biometrics 1997; 53:983 -97
Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12 -month prevalence of 
DSM -III-R psy chiatric disorders in the [LOCATION_002]: results from the National Comorbidity  
Study . Arch Gen Psy chiatry  1994;51:8-19.
Kessler RC, Chiu WJ, Demler O, et al . Prevalence, severit y, and comorbidity  of 
12-month DSM -IV disorders in the National Comorbidity  Survey . Arch Gen Psy chiatry  
2005;62(6): 617 -
27.
Laughren TP. The scientific and ethical basis for placebo -controlled trials in depression and 
schizophrenia: an FDA perspective. Eur Psy chiatry . 2001; 16(7):[ADDRESS_177620], Carson WH, et al. The efficacy  and safet y of aripi[INVESTIGATOR_153881] y in major depressive disorder: a second multicenter, randomized, double -blind, 
placebo -controlled study .J Clin Psy chopharmacol 2008;28(2):156 - 65.
Masand PS. Tolerability  and adherence issues in antidepressant therapy . Clin Ther 
2003;25(8):2289 -
304.
McInty re RS and O’Donovan C . The human cost of not achieving full remission in depress ion. 
Can J Psy chiatry  2004;49(suppl 1):10S -16S.
Montgomery  SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J 
Psychiatry  1979; 134:382 -
9
Murray  CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990- 2010: burden of diseases, 
injuries, and risk factors . JAMA 2013;310(6):591 - 608.
Naurex, Inc 107
RAP- MD-01 Protocol Amendment 3 07 Dec 2018Newport DJ, Carpenter LL, McDonald WM, et al . Ketamine and other NMDA antagonists: earl y 
clinical trials and possible mechanisms in d epression. Am J Psy chiatry  2015;172(10):950-66.
Overall JE andGorham DR. The brief ps ychiatric rating scale. Psychological Reports 
1962;10:799 -812.
Rapastinel: I nvestigator’s Brochure. Edition 7. Evanston, IL : Naurex, I nc; 01 Jul2014. 
Rexulti [package insert] . Toky o, Japan; Otsuka Pharmaceutical Co., L td. August 2015.
Rosenzweig -Lipson S, Beyer CG, Hughes ZA, et al . Differentiating antidepressants of the future: 
efficacy  and safet y
. Pharmacol Ther 2007;113(1):134-53.
Rush AJ, Trivedi MH, Wisniewski SR, et al . Acute and longer -term outcomes in depressed 
outpatients 
requiring one or several treatment steps: a STAR*D report . 
Am J Psy chiatry  2006;163:1905 -17.
Sachdev P . The epi[INVESTIGATOR_153882] -induced akathisia part II. Chronic, tardive, and withdrawal 
akathisias. Schizophren Bull 1995;21(3):451 -61.
Seroquel [package insert] . Wilmington, DE; [COMPANY_008] Pharmaceuticals LP . October 2013.
Smith DW andJones K L (1982). Recognizable Patterns of Human Malformation. (3 ed.) 
Philadelphia: Saunders.
Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentations after the f ailure of SSRIs 
for depression . N Engl J Med 2006;354(12):1243-52.
Videbech P and Ravnkilde B . Hippocampal volume and depression: a meta -analysis of MRI 
studies . Am J Psy chiatry  2004;161:1957 - 66.
World Health Organization. Mental health: new understanding, new hope . World Health Report 
2001
1
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes 07Dec 2018SUMMARY OF CHANGES TO PROTOCOL 
RAP -MD-01
A Randomized, Double -blind, Placebo -controlled, Multicenter Study of Rapastinel 
as Adjunctive Therapy in Major Depressive Disorder
Amendment #3, 07 Dec2018
IND # 107,974
Sponsor: Naurex Inc., an indirect 
subsidiary of Allergan, plc
5 Giralda Farms
Madison, NJ [ZIP_CODE]
Original Protocol Date: 28 Apr 2016
Amendment #
1 28 Sep 2016
Amendment #[ADDRESS_177621] 2018
Confidentiality Statement
This document is the property of Allergan, plc and may not —in full or part— be passed 
on, reproduced, published, distributed, or submitted to any regulatory authority without 
the express written permission of Allergan, plc.
2
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes 07Dec [ZIP_CODE].0 INTRODUCTION
Amendment #3 specifies the following change sto the RAP -MD-01 protocol amendment 
#2,dated 12Oct2018: 
Change in the sample size
Change in the statistical description of the determination of sample size
[ADDRESS_177622] been made globall y to the protocol:
None .
[ADDRESS_177623] been removed from the protocol:
None .
[ADDRESS_177624] been added to the protocol:
None.
[ADDRESS_177625] been made to the protocol.
5.1 SECTION 9.1.2 DOUBLE -BLIND TREATMENT PERI OD
Rationale: This section has been amended to change the sample size .
This section has been amended as follows:
Approximately  360460 patients are planned for enrollment in the double -blind treatment 
period ( 350230 patients each in the rapastinel 450 mg and placebo groups). Patients will 
be randomized in a ratio of 1:1 to 1 of 2 treatment groups: rapastinel 450 mg IV weekly  
or placebo IV weekl y (both adjunctive to ongoing ADT).
5.2 SECTION 9.7.9 DETERM INATION OF SAMPLE S IZE
Rationale: This section has been amended to reflect the results of the blinded interim 
analysis.
This section has been amended as follows:
The prim aryefficacy para meteristhechange from Baseline toEnd of Study in
MADRS total score. The sample size estimation is based on the comparison of the 
primary efficacy endpoint between the rapastinel 450 mg and the placebo treatment 
groups. Asamplesizeof 180 random ized patients in each group willprovide 90% 
power to detect a treatmen t difference of 3.[ADDRESS_177626] deviation of 8.7 for the change from Baseline to End of Study . This assumed 
pooled SD of 8.7 is supported by [CONTACT_153913] 9.7.8 
(Interim Analysis): the pooled SDs were observed to be 7.4, 8.0, and 8.7 for Studies RAP -
MD-01, RAP -MD-02, and RAP -MD-03 respectively. The simulation alsoassumeda
correlation of 0.5 between therepeated measures and a common dropout rate of 
15% from Baseline to End of Study for all treatment groups. 
The originally  proposed primary  efficacy  variable is the change from baseline in the 
MADRS total score at [ADDRESS_177627] deviation (SD) of 10 points, which provide s 
99% power to detect a difference of 3.[ADDRESS_177628] visit, Day  21, as recommended by  [CONTACT_1622], 
EMA, and PDMA, and included in Amendment 2 of the protocol. At the same time of 
7
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes 07Dec 2018Amendment 2, a blinded data review was conducted for Studies RAP -MD-01, RAP -MD-
02, and RAP -MD-03. The pooled SD for the 3 studies were 7.4, 8.0, and 8.7, 
respectivel y, all smaller than the originally assumed 10 points. Sample size was re -
calculated using 8.7 as the common SD. The calculation used MMRM model with 
simulations; it also assumed correlation of 0.5 between the repeated measures and an 
overall discontinuation rate of 15%. To have 90% power, the total sample size required is 
360 patients. However, the study  had already  enrolled more than 440 patients with less 
than 5% of overall discontinuation rate, sur passing the re -estimated sample size of 360 
patients. The study  enrollment was halted as soon as operationall y feasible. The final 
sample size is approximately 460 patients (230 patients per treatment group).